{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:54:28Z","timestamp":1787842468252,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40266-019-00723-3","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T02:02:26Z","timestamp":1574388146000},"page":"43-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-827X","authenticated-orcid":false,"given":"Minji","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4353","authenticated-orcid":false,"given":"Sukhyang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,22]]},"reference":[{"key":"723_CR1","doi-asserted-by":"crossref","unstructured":"Statistics Korea. Korean Statistical Information Service. 2018. http:\/\/kosis.kr\/eng\/statisticsList\/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ETITLE&parmTabId=M_01_01#SelectStatsBoxDiv.\u00a0Accessed 04 Jul 2019.","DOI":"10.35338\/EJCTS.2019.1101"},{"issue":"1","key":"723_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"10042","key":"723_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0140-6736(16)30468-8","volume":"388","author":"PM Rothwell","year":"2016","unstructured":"Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. The Lancet. 2016;388(10042):365\u201375.","journal-title":"The Lancet."},{"issue":"7329","key":"723_CR4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Trialists\u2019 Collaboration A","year":"2002","unstructured":"Trialists\u2019 Collaboration A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ."},{"issue":"8","key":"723_CR5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1161\/01.STR.0000174189.81153.85","volume":"36","author":"PB Gorelick","year":"2005","unstructured":"Gorelick PB, Weisman SM. Risk of hemorrhagic stroke with aspirin use: an update. Stroke. 2005;36(8):1801\u20137.","journal-title":"Stroke"},{"key":"723_CR6","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. The Lancet. 2009;373:1849\u201360.","journal-title":"The Lancet"},{"issue":"7","key":"723_CR7","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurheartj\/ehy813","volume":"40","author":"AN Mahmoud","year":"2018","unstructured":"Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2018;40(7):607\u201317.","journal-title":"Eur Heart J"},{"issue":"3","key":"723_CR8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","volume":"321","author":"SL Zheng","year":"2019","unstructured":"Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277\u201387.","journal-title":"JAMA"},{"issue":"5","key":"723_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/jcm8050609","volume":"8","author":"MH Lin","year":"2019","unstructured":"Lin MH, Lee CH, Lin C, Zou YF, Lu CH, Hsieh CH, et al. Low-dose aspirin for the primary prevention of cardiovascular disease in diabetic individuals: a meta-analysis of randomized control trials and trial sequential analysis. J Clin Med. 2019;8(5):609.","journal-title":"J Clin Med"},{"issue":"5","key":"723_CR10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518\u201327.","journal-title":"Lancet Oncol"},{"issue":"9826","key":"723_CR11","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","volume":"379","author":"PM Rothwell","year":"2012","unstructured":"Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet. 2012;379(9826):1602\u201312.","journal-title":"The Lancet."},{"issue":"12","key":"723_CR12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/M15-2117","volume":"164","author":"J Chubak","year":"2016","unstructured":"Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the US Preventive Services Task Force. Ann Intern Med. 2016;164(12):814\u201325.","journal-title":"Ann Intern Med"},{"issue":"16","key":"723_CR13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"723_CR14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","volume":"164","author":"K Bibbins-Domingo","year":"2016","unstructured":"Bibbins-Domingo K, Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. A Intern Med. 2016;164(12):836\u201345.","journal-title":"A Intern Med."},{"issue":"29","key":"723_CR15","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J"},{"key":"723_CR16","first-page":"e596","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, Michos ED, Buroker AB, Miedema MD, et al. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;140:e596\u2013646.","journal-title":"J Am Coll Cardiol"},{"key":"723_CR17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pmedr.2016.12.023","volume":"5","author":"M Stuntz","year":"2017","unstructured":"Stuntz M, Bernstein B. Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012\u20132015. Prev Med Rep. 2017;5:183\u20136.","journal-title":"Prev Med Rep"},{"issue":"23","key":"723_CR18","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1001\/jama.2014.15690","volume":"312","author":"Y Ikeda","year":"2014","unstructured":"Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60\u00a0years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312(23):2510\u201320.","journal-title":"JAMA"},{"issue":"3","key":"723_CR19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40256-018-0313-0","volume":"19","author":"M Sugawara","year":"2019","unstructured":"Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, et al. Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70). Am J Cardiovasc Drugs. 2019;19(3):299\u2013311.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"723_CR20","doi-asserted-by":"crossref","first-page":"e016640","DOI":"10.1136\/bmjopen-2017-016640","volume":"7","author":"SC Seong","year":"2017","unstructured":"Seong SC, Kim Y-Y, Park SK, Khang YH, Kim HC, Park JH, et al. Cohort profile: the National Health Insurance Service-National Health Screening cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7(9):e016640.","journal-title":"BMJ Open"},{"issue":"2","key":"723_CR21","first-page":"e15","volume":"46","author":"J Lee","year":"2016","unstructured":"Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2016;46(2):e15.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"723_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12913-017-2073-y","volume":"17","author":"KL Tang","year":"2017","unstructured":"Tang KL, Quan H, Rabi DM. Measuring medication adherence in patients with incident hypertension: a retrospective cohort study. BMC Health Serv Res. 2017;17(1):135.","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"723_CR23","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","volume":"57","author":"V Sundararajan","year":"2004","unstructured":"Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"723_CR24","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350.","journal-title":"J Am Coll Cardiol"},{"key":"723_CR25","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jep.12072","volume":"19","author":"A Linden","year":"2013","unstructured":"Linden A, Samuels SJ. Using balance statistics to determine the optimal number of controls in matching studies. J Eval in ClinPract. 2013;19:968\u201375.","journal-title":"J Eval in ClinPract"},{"issue":"3","key":"723_CR26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ahj.2009.11.030","volume":"159","author":"T Teramoto","year":"2010","unstructured":"Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)\u2014a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159(3):361\u2013369.e4.","journal-title":"Am Heart J"},{"issue":"6","key":"723_CR27","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/HJH.0000000000002034","volume":"37","author":"K Ando","year":"2019","unstructured":"Ando K, Shimada K, Yamazaki T, Uchiyama S, Uemura Y, Ishizuka N, et al. Influence of blood pressure on the effects of low-dose asprin in elderly patients with multiple atherosclerotic risks. J Hypertens. 2019;37(6):1301\u20137.","journal-title":"J Hypertens"},{"issue":"13","key":"723_CR28","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293\u2013304.","journal-title":"N Engl J Med"},{"issue":"3","key":"723_CR29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"JS Berger","year":"2006","unstructured":"Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306\u201313.","journal-title":"JAMA"},{"issue":"9118","key":"723_CR30","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, Dahl\u00f6f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet. 1998;351(9118):1755\u201362.","journal-title":"The Lancet"},{"issue":"18","key":"723_CR31","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","volume":"300","author":"H Ogawa","year":"2008","unstructured":"Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134\u201341.","journal-title":"JAMA"},{"issue":"3","key":"723_CR32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","author":"Group* SCotPHSR","year":"1989","unstructured":"Group* SCotPHSR. Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. N Engl J Med. 1989;321(3):129\u201335.","journal-title":"N Engl J Med."},{"issue":"16","key":"723_CR33","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"Group ASC","year":"2018","unstructured":"Group ASC. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med"},{"issue":"10152","key":"723_CR34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","volume":"392","author":"JM Gaziano","year":"2018","unstructured":"Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036\u201346.","journal-title":"The Lancet"},{"issue":"16","key":"723_CR35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","volume":"379","author":"JJ McNeil","year":"2018","unstructured":"McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509\u201318.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"723_CR36","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142019. Diabetes Care. 2019;42(Supplement 1):S103\u201323.","journal-title":"Diabetes Care."},{"issue":"7","key":"723_CR37","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/2047487318816387","volume":"26","author":"S Upadhaya","year":"2019","unstructured":"Upadhaya S, Madala S, Baniya R, Saginala K, Khan J. Impact of acetylsalicylic acid on primary prevention of cardiovascular diseases: a meta-analysis of randomized trials. Eur J Prev Cardiol. 2019;26(7):746\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"723_CR38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ijc.32083","volume":"145","author":"KK Tsoi","year":"2019","unstructured":"Tsoi KK, Ho JM, Chan FC, Sung JJ. Long-term use of low-dose aspirin for cancer prevention: a 10-year population cohort study in Hong Kong. Int J Cancer. 2019;145(1):267\u201373.","journal-title":"Int J Cancer"},{"issue":"2","key":"723_CR39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.4143\/crt.2015.117","volume":"48","author":"YI Kim","year":"2016","unstructured":"Kim YI, Kim SY, Kim JH, Lee JH, Kim YW, Ryu KW, et al. Long-term low-dose aspirin use reduces gastric cancer incidence: a nationwide cohort study. Cancer Res Treat. 2016;48(2):798.","journal-title":"Cancer Res Treat"},{"issue":"9","key":"723_CR40","doi-asserted-by":"crossref","first-page":"e0203957","DOI":"10.1371\/journal.pone.0203957","volume":"13","author":"PC Elwood","year":"2018","unstructured":"Elwood PC, Pickering JE, Morgan G, Galante J, Weightman AL, Morris D, et al. Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients? PLoS One. 2018;13(9):e0203957.","journal-title":"PLoS One"},{"issue":"2","key":"723_CR41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114\u201324.","journal-title":"N Engl J Med"},{"key":"723_CR42","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","volume":"337","author":"J Belch","year":"2008","unstructured":"Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.","journal-title":"BMJ"},{"issue":"9098","key":"723_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","volume":"351","author":"Framework MRCsGPR","year":"1998","unstructured":"Framework MRCsGPR. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Lancet. 1998;351(9098):233\u201341.","journal-title":"The Lancet"},{"issue":"11","key":"723_CR44","doi-asserted-by":"crossref","first-page":"e0166166","DOI":"10.1371\/journal.pone.0166166","volume":"11","author":"PC Elwood","year":"2016","unstructured":"Elwood PC, Morgan G, Galante J, Chia JW, Dolwani S, Graziano JM, et al. Systematic review and meta-analysis of randomised trials to ascertain fatal gastrointestinal bleeding events attributable to preventive low-dose aspirin: no evidence of increased risk. PLoS One. 2016;11(11):e0166166.","journal-title":"PLoS One"},{"key":"723_CR45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1120","author":"WY Huang","year":"2019","unstructured":"Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. JAMA Neurol. 2019. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1120.","journal-title":"JAMA Neurol."},{"issue":"1","key":"723_CR46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000085310","volume":"25","author":"AL Klatsky","year":"2005","unstructured":"Klatsky AL, Friedman GD, Sidney S, Kipp H, Kubo A, Armstrong MA. Risk of hemorrhagic stroke in Asian American ethnic groups. Neuroepidemiology. 2005;25(1):26\u201331.","journal-title":"Neuroepidemiology."},{"issue":"2","key":"723_CR47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","volume":"9","author":"CJ van Asch","year":"2010","unstructured":"van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet Neurol. 2010;9(2):167\u201376.","journal-title":"The Lancet Neurol"},{"issue":"1","key":"723_CR48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5853\/jos.2016.00864","volume":"19","author":"SJ An","year":"2017","unstructured":"An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. Journal of Stroke. 2017;19(1):3.","journal-title":"Journal of Stroke."},{"issue":"5","key":"723_CR49","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cgh.2018.05.061","volume":"17","author":"LC Soriano","year":"2019","unstructured":"Soriano LC, Lanas A, Soriano-Gabarr\u00f3 M, Rodr\u00edguez LAG. Incidence of upper and lower gastrointestinal bleeding in new users of low-dose aspirin. Clin Gastroenterol Hepatol. 2019;17(5):887\u2013889.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"723_CR50","doi-asserted-by":"crossref","first-page":"804","DOI":"10.7326\/M18-2637","volume":"169","author":"M Pignone","year":"2018","unstructured":"Pignone M, DeWalt DA. More evidence to help guide decision making about aspirin for primary prevention. Ann Intern Med. 2018;169(11):804\u20135.","journal-title":"Ann Intern Med"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-019-00723-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-019-00723-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T17:32:00Z","timestamp":1665077520000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-019-00723-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1007\/s40266-019-00723-3","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,22]]},"assertion":[{"value":"22 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jung and Lee declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}